Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug;23(8):4945-4954.
doi: 10.1111/jcmm.14312. Epub 2019 Jun 14.

MicroRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma by targeting Cyclin D1

Affiliations

MicroRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma by targeting Cyclin D1

Weiping Chang et al. J Cell Mol Med. 2019 Aug.

Abstract

MicroRNAs (miRNAs) are powerful regulators in the tumorigenesis of cholangiocarcinoma (CCA). Previous studies report that miR-551b-3p acts as an oncogenic factor in ovarian cancer, but plays a tumour suppressive role in gastric cancer. However, the expression pattern and potential function of miR-551b-3p were still unclear in CCA. Therefore, this study aimed to explore the expression of miR-551b-3p and its role as well as molecular mechanism in CCA. Analysis of TCGA dataset suggested that miR-551b-3p was under-expressed in CCA tissues compared to normal bile duct tissues. Furthermore, our data confirmed the decreased levels of miR-551b-3p in CCA samples and cell lines. Interestingly, TCGA data suggested that low miR-551b-3p level indicated reduced overall survival of CCA patients. Gain- and loss-of-function experiments found that miR-551b-3p inhibited the proliferation, G1-S phase transition and induced apoptosis of CCA cells. In vivo experiments revealed that ectopic expression of miR-551b-3p inhibited tumour growth of CCA in mice. Further investigation demonstrated that miR-551b-3p directly bond to the 3'-UTR of Cyclin D1 (CCND1) mRNA and negatively regulated the abundance of CCND1 in CCA cells. An inverse correlation between miR-551b-3p expression and the level of CCND1 mRNA was detected in CCA tissues from TCGA dataset. Notably, CCND1 knockdown showed similar effects to miR-551b-3p overexpression in HuCCT-1 cells. CCND1 restoration rescued miR-551b-3p-induced inhibition of proliferation, G1 phase arrest and apoptosis in HuCCT-1 cells. In summary, miR-551b-3p inhibits the expression of CCND1 to suppress CCA cell proliferation and induce apoptosis, which may provide a theoretical basis for improving CCA treatment.

Keywords: Cyclin D1; cholangiocarcinoma; microRNA-551b-3p; tumour growth.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The expression of miR‐551b‐3p in CCA. A, CCA samples (n = 36) and normal bile duct tissues (n = 9) in TCGA dataset from starBase V3.0 platform showed that miR‐551b‐3p expression was significantly down‐regulated in tumour tissues. B, The expression of miR‐551b‐3p was detected in CCA tissues (n = 15) and normal bile duct tissues (n = 15) using qRTPCR. C, The levels of miR‐551b‐3p between CCA cell lines (HuCCT‐1, RBE, HCCC‐9810 and QBC939) and HiBEC cells were analysed by qRTPCR. *P < 0.05. C, TCGA data from starBase V3.0 platform indicated that CCA patients with low miR‐551b‐3p level had an obvious poorer overall survival compared to miR‐551b‐3p high‐expressing patients
Figure 2
Figure 2
miR‐551b‐3p overexpression suppresses proliferation, cell cycle progression and induces apoptosis of CCA cells. A, Vectors containing miR‐551b‐3p or control mimics were transfected into HuCCT1 and QBC939 cells and detected by qRTPCR for miR‐551b‐3p expression. B and C, CCK‐8 and EdU assays demonstrated that miR‐551b‐3p overexpression inhibited CCA cell proliferation. D, miR‐551b‐3p overexpression induced the apoptosis of CCA cells as suggested by flow cytometry analysis. E, The G1 to S phase transition was blocked by miR‐551b‐3p overexpression in HuCCT1 and QBC939 cells. *P < 0.05
Figure 3
Figure 3
miR‐551b‐3p knockdown enhances proliferation, cell cycle progression and inhibits apoptosis of RBE cells. A, Vectors containing miR‐551b‐3p inhibitors or negative control (NC) were transduced into RBE cells and detected for miR‐551b‐3p expression using qRTPCR. B and C, CCK‐8 and EdU assays demonstrated that miR‐551b‐3p knockdown enhanced CCA cell proliferation. D, miR‐551b‐3p knockdown inhibited the apoptosis of RBE cells as suggested by flow cytometry analysis. E, miR‐551b‐3p knockdown facilitated the G1 to S phase transition in RBE cells. *P < 0.05
Figure 4
Figure 4
miR‐551b‐3p restoration restrains tumour growth of HuCCT‐1 cells. A, HuCCT‐1 cells that were transfected with vectors containing miR‐551b‐3p or control mimics were subcutaneously implanted into nude mice . Both tumour volume and tumour weight in miR‐551b‐3p group were obviously less than those in control group. B, The expression of miR‐551b‐3p in xenograft tumour tissues from miR‐551b‐3p group was significantly higher than that in control group. C, IHC analysis showed that strong staining of Ki‐67 was observed in most of tumour cells in control group, whereas only several tumour cells showed weak staining of Ki‐67 in miR‐551b‐3p group. *P < 0.05
Figure 5
Figure 5
CCND1 is recognized as a target of miR‐551b‐3p in CCA cells. A, Bioinformatic analysis in starBase V3.0 platform indicated the potential binding sequences between miR‐551b‐3p and 3′UTR of CCND1. B, TCGA data from starBase V3.0 platform indicated that the expression of miR‐551b‐3p was negatively correlated with the level of CCND1 mRNA in CCA tissues. C, miR‐551b‐3p or control mimics were transfected into HuCCT‐1 and QBC939 cells and detected for CCND1 expression using qRTPCR and immunoblotting. D, miR‐551b‐3p inhibitors or negative control (NC) was transduced into RBE cells and detected for CCND1 expression using qRTPCR and immunoblotting. E, The expression of CCND1 protein in xenograft tumour tissues from miR‐551b‐3p group was significantly lower than that in control group. (F) Co‐transfection of miR‐551b‐3p mimics/inhibitors and wild‐type (wt) or mutated (mt) 3′UTR of CCND1 was performed in HuCCT‐1 cells and the relative luciferase activity was measured. *P < 0.05
Figure 6
Figure 6
CCND1 knockdown suppresses the growth of HuCCT‐1 cells. A, CCND1 siRNA or non‐targeting (NT) siRNA was transfected into HuCCT‐1 cells and detected for CCND1 protein using immunoblotting. B, CCK‐8, (C) EdU, (D) flow cytometry apoptosis and (E) cell cycle analysis were carried out to detect the proliferation, apoptosis and cell cycle progression of HuCCT‐1 cells. *P < 0.05
Figure 7
Figure 7
CCND1 restoration rescues miR‐551b‐3p induced growth arrest and apoptosis of HuCCT‐1 cells. A, CCND1 expression was rescued by transfecting vectors in miR‐551b‐3p overexpressing HuCCT‐1 cells as detected by immunoblotting. B, CCK‐8, (C) EdU, (D) flow cytometry apoptosis and (E) cell cycle analysis were carried out to detect the proliferation, apoptosis and cell cycle progression of HuCCT‐1 cells. CCND1 restoration abrogated the effects of miR‐551b‐3p on HuCCT‐1 cells. *P < 0.05

Similar articles

Cited by

References

    1. Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS‐CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261‐280. - PubMed
    1. Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19:2. - PubMed
    1. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857‐866. - PubMed
    1. Xu Q, Zhu Q, Zhou Z, et al. MicroRNA‐876‐5p inhibits epithelial‐mesenchymal transition and metastasis of hepatocellular carcinoma by targeting BCL6 corepressor like 1. Biomed Pharmacother. 2018;103:645‐652. - PubMed
    1. Liu Z, Wang Y, Dou C, et al. MicroRNA‐1468 promotes tumor progression by activating PPAR‐gamma‐mediated AKT signaling in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37:49. - PMC - PubMed

Publication types

MeSH terms